A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. / Mrowietz, U; de Jong, E M G J; Kragballe, K; Langley, R; Nast, A; Puig, L; Reich, K; Schmitt, J; Warren, R B.

In: Journal of the European Academy of Dermatology and Venereology, 26.02.2013.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Mrowietz, U, de Jong, EMGJ, Kragballe, K, Langley, R, Nast, A, Puig, L, Reich, K, Schmitt, J & Warren, RB 2013, 'A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis', Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12118

APA

Mrowietz, U., de Jong, E. M. G. J., Kragballe, K., Langley, R., Nast, A., Puig, L., Reich, K., Schmitt, J., & Warren, R. B. (2013). A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12118

CBE

Mrowietz U, de Jong EMGJ, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB. 2013. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12118

MLA

Vancouver

Mrowietz U, de Jong EMGJ, Kragballe K, Langley R, Nast A, Puig L et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2013 Feb 26. https://doi.org/10.1111/jdv.12118

Author

Mrowietz, U ; de Jong, E M G J ; Kragballe, K ; Langley, R ; Nast, A ; Puig, L ; Reich, K ; Schmitt, J ; Warren, R B. / A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. In: Journal of the European Academy of Dermatology and Venereology. 2013.

Bibtex

@article{9cf2742bfbc84f8f803b1cbe6e3cdc8e,
title = "A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis",
abstract = "BACKGROUND: There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. OBJECTIVE: To provide practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis. METHODS: Dermatologists from 33 countries contributed to the Transitioning Therapies programme. Fourteen questions were identified. Answers were drafted based on systematic literature reviews (7/14 questions) and expert opinion (7/14 questions). Using a modified Delphi procedure, dermatologists from 30 countries voted on their level of agreement with each draft answer (scale: 1-9, strong disagreement to strong agreement). Consensus was defined as ≥75% of participants scoring within the 7-9 range. RESULTS: Consensus was achieved on the answers to all questions. Recommendations for the use of cyclosporine and methotrexate were agreed. Transitioning from a conventional systemic therapy to a biological agent may be done directly or with an overlap (if transitioning is required because of lack of efficacy) or potentially with a treatment-free interval (if transitioning is required for safety reasons). Combination therapy may be beneficial. Continuous therapy for patients on biologicals is strongly recommended. However, during successful maintenance with biological monotherapy, a dosage reduction may be considered to limit drug exposure, although this may carry the risk of decreased efficacy. Switching biologicals for reasons of efficacy should be done without a washout period, but switching for reasons of safety may require a treatment-free interval. CONCLUSION: This consensus provides practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis, based on literature reviews and the expert opinion of dermatologists from across the globe.",
author = "U Mrowietz and {de Jong}, {E M G J} and K Kragballe and R Langley and A Nast and L Puig and K Reich and J Schmitt and Warren, {R B}",
note = "{\textcopyright} 2013 The Authors Journal of the European Academy of Dermatology and Venereology {\textcopyright} 2013 European Academy of Dermatology and Venereology.",
year = "2013",
month = feb,
day = "26",
doi = "10.1111/jdv.12118",
language = "English",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

AU - Mrowietz, U

AU - de Jong, E M G J

AU - Kragballe, K

AU - Langley, R

AU - Nast, A

AU - Puig, L

AU - Reich, K

AU - Schmitt, J

AU - Warren, R B

N1 - © 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology.

PY - 2013/2/26

Y1 - 2013/2/26

N2 - BACKGROUND: There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. OBJECTIVE: To provide practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis. METHODS: Dermatologists from 33 countries contributed to the Transitioning Therapies programme. Fourteen questions were identified. Answers were drafted based on systematic literature reviews (7/14 questions) and expert opinion (7/14 questions). Using a modified Delphi procedure, dermatologists from 30 countries voted on their level of agreement with each draft answer (scale: 1-9, strong disagreement to strong agreement). Consensus was defined as ≥75% of participants scoring within the 7-9 range. RESULTS: Consensus was achieved on the answers to all questions. Recommendations for the use of cyclosporine and methotrexate were agreed. Transitioning from a conventional systemic therapy to a biological agent may be done directly or with an overlap (if transitioning is required because of lack of efficacy) or potentially with a treatment-free interval (if transitioning is required for safety reasons). Combination therapy may be beneficial. Continuous therapy for patients on biologicals is strongly recommended. However, during successful maintenance with biological monotherapy, a dosage reduction may be considered to limit drug exposure, although this may carry the risk of decreased efficacy. Switching biologicals for reasons of efficacy should be done without a washout period, but switching for reasons of safety may require a treatment-free interval. CONCLUSION: This consensus provides practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis, based on literature reviews and the expert opinion of dermatologists from across the globe.

AB - BACKGROUND: There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. OBJECTIVE: To provide practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis. METHODS: Dermatologists from 33 countries contributed to the Transitioning Therapies programme. Fourteen questions were identified. Answers were drafted based on systematic literature reviews (7/14 questions) and expert opinion (7/14 questions). Using a modified Delphi procedure, dermatologists from 30 countries voted on their level of agreement with each draft answer (scale: 1-9, strong disagreement to strong agreement). Consensus was defined as ≥75% of participants scoring within the 7-9 range. RESULTS: Consensus was achieved on the answers to all questions. Recommendations for the use of cyclosporine and methotrexate were agreed. Transitioning from a conventional systemic therapy to a biological agent may be done directly or with an overlap (if transitioning is required because of lack of efficacy) or potentially with a treatment-free interval (if transitioning is required for safety reasons). Combination therapy may be beneficial. Continuous therapy for patients on biologicals is strongly recommended. However, during successful maintenance with biological monotherapy, a dosage reduction may be considered to limit drug exposure, although this may carry the risk of decreased efficacy. Switching biologicals for reasons of efficacy should be done without a washout period, but switching for reasons of safety may require a treatment-free interval. CONCLUSION: This consensus provides practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis, based on literature reviews and the expert opinion of dermatologists from across the globe.

U2 - 10.1111/jdv.12118

DO - 10.1111/jdv.12118

M3 - Journal article

C2 - 23437792

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

ER -